Angiotensin II Type 1 Receptor Agonist TRV027

**Semantic type:** Pharmacologic Substance

**Definition:** A beta-arrestin-biased, angiotensin II type 1 receptor (AT1R) agonist, with potential vasodilating and cardiopulmonary protective activities. Upon administration, AT1R agonist TRV027 competitively binds to AT1R and selectively modulates AT1R signaling, thereby inhibiting angiotensin II (Ang II) activity and activating the AT1R/beta-arrestin signaling pathway. Inhibition of Ang II activity may reduce vasoconstriction, cardiomyocyte hypertrophy, fibrosis in the heart and lungs, and coagulopathy. Activating the AT1R/beta-arrestin signaling pathway may promote AT1R/beta-arrestin-mediated reparative activities and result in protective effects on heart and lung tissues. It may also decrease abnormal blood clotting. Altogether, TRV027 may restore the homeostasis of the renin-angiotensin-aldosterone system (RAAS), which may be overactivated in severe Coronavirus disease 2019 (COVID-19).

**Synonyms:** - AT1 Agonist TRV027 - AT1R Agonist TRV027 - Angiotensin Type 1 Receptor Agonist TRV027 - Beta-arrestin-biased Ang II Type 1 Receptor Agonist TRV027 - TRV 027 - TRV-027 - TRV027